VC-backed technology company developing disruptive technologies to boost recombinant biologics production using proprietary technologies based on Baculovirus vector expression systems (BVES) in insect cells.

Supported by a first in class Strategic Advisory Board combining investment and operational experience in developing companies in animal and human health.

Two proprietary and patented technology platforms, Top-Bac® and CrisBio®, to respond to industry’s challenges in the production of biologicals: development time, scalability, versatility and cost.

Data available in various protein classes and indications across Animal Health, Human Health, Diagnostics and Biocomponents.